Cell-associated HIV RNA: a dynamic biomarker of viral persistence
Open Access
- 15 April 2013
- journal article
- review article
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 41
Abstract
In most HIV-infected individuals adherent to modern antiretroviral therapy (ART), plasma viremia stays undetectable by clinical assays and therefore, additional virological markers for monitoring and predicting therapy responses and for measuring the degree of HIV persistence in patients on ART should be identified. For the above purposes, quantitation of cell-associated HIV biomarkers could provide a useful alternative to measurements of viral RNA in plasma. This review concentrates on cell-associated (CA) HIV RNA with the emphasis on its use as a virological biomarker. We discuss the significance of CA HIV RNA as a prognostic marker of disease progression in untreated patients and as an indicator of residual virus replication and the size of the dynamic viral reservoir in ART-treated patients. Potential value of this biomarker for monitoring the response to ART and to novel HIV eradication therapies is highlighted.Keywords
This publication has 169 references indexed in Scilit:
- Towards an HIV cure: a global scientific strategyNature Reviews Immunology, 2012
- Short-Course Raltegravir Intensification Does Not Increase 2 Long Terminal Repeat Episomal HIV-1 DNA in Patients on Effective Antiretroviral TherapyClinical Infectious Diseases, 2011
- A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell ResponseThe Journal of Infectious Diseases, 2011
- HIV reservoirs and latency modelsVirology, 2011
- HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV ControllersClinical Infectious Diseases, 2011
- Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral TherapyThe Journal of Infectious Diseases, 2010
- Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral TherapyClinical Infectious Diseases, 2010
- HIV rebounds from latently infected cells, rather than from continuing low-level replicationProceedings of the National Academy of Sciences, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008